@article{VSGU_2011_8_a19,
author = {A. O. Osipov and P. P. Purygin and A. V. Dubishchev and A. A. Osipova},
title = {{\CYRF}{\cyra}{\cyrr}{\cyrm}{\cyra}{\cyrk}{\cyro}{\cyrl}{\cyro}{\cyrg}{\cyri}{\cyrch}{\cyre}{\cyrs}{\cyrk}{\cyra}{\cyrya} {\cyra}{\cyrk}{\cyrt}{\cyri}{\cyrv}{\cyrn}{\cyro}{\cyrs}{\cyrt}{\cyrsftsn} {\cyrp}{\cyrr}{\cyro}{\cyri}{\cyrz}{\cyrv}{\cyro}{\cyrd}{\cyrn}{\cyrery}{\cyrh} {\cyrp}{\cyri}{\cyrr}{\cyri}{\cyrm}{\cyri}{\cyrd}{\cyri}{\cyrn}{\cyra}},
journal = {Vestnik Samarskogo universiteta. Estestvennonau\v{c}na\^a seri\^a},
pages = {167--172},
year = {2011},
number = {8},
language = {ru},
url = {http://geodesic.mathdoc.fr/item/VSGU_2011_8_a19/}
}
TY - JOUR AU - A. O. Osipov AU - P. P. Purygin AU - A. V. Dubishchev AU - A. A. Osipova TI - Фармакологическая активность производных пиримидина JO - Vestnik Samarskogo universiteta. Estestvennonaučnaâ seriâ PY - 2011 SP - 167 EP - 172 IS - 8 UR - http://geodesic.mathdoc.fr/item/VSGU_2011_8_a19/ LA - ru ID - VSGU_2011_8_a19 ER -
%0 Journal Article %A A. O. Osipov %A P. P. Purygin %A A. V. Dubishchev %A A. A. Osipova %T Фармакологическая активность производных пиримидина %J Vestnik Samarskogo universiteta. Estestvennonaučnaâ seriâ %D 2011 %P 167-172 %N 8 %U http://geodesic.mathdoc.fr/item/VSGU_2011_8_a19/ %G ru %F VSGU_2011_8_a19
A. O. Osipov; P. P. Purygin; A. V. Dubishchev; A. A. Osipova. Фармакологическая активность производных пиримидина. Vestnik Samarskogo universiteta. Estestvennonaučnaâ seriâ, no. 8 (2011), pp. 167-172. http://geodesic.mathdoc.fr/item/VSGU_2011_8_a19/
[1] Cox Michael, Nelson David R., Cox M. N., Lehninger: Principles of Biochemistry, fifth, WH Freeman, 2008
[2] Druker B. J., Lydon N. B., “Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia”, J. Clin. Invest., 105:1 (2000), 3–7 | DOI
[3] W. Pao et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib”, Proc Natl Acad Sci USA, 101:36 (2004), 13306–13311 | DOI
[4] Ibrahim D. A., Ismail N. S. M., “Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors”, European Journal of Medicinal Chemistry, 2011
[5] M. M. Kemp et al., “A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold”, Bioorg. Med. Chem. Lett., 21:14 (2011), 4164–4169 | DOI
[6] T. V. Hughes et al., “A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity”, Bioorg. Med. Chem. Lett., 18:17 (2008), 4896–4899 | DOI
[7] 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity, J. Med. Chem., 47:7 (2004), 1662–1675 | DOI
[8] A. Kolokotronis et al., “Comparison in vivo and in vitro of the antibacterial action of the antiseptics hexetidine and povidone-iodine”, ZWR, 92:6 (1983), 44–46
[9] V. E. Semenov et al., “Antimicrobial activity of pyrimidinophanes with thiocytosine and uracil moieties”, Eur. J. Med. Chem., 46:9 (2011), 4715–4724 | DOI
[10] J. L. Paulsen et al., “In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans”, Bioorg. Med. Chem., 17:14 (2009), 4866–4872 | DOI
[11] B. Singh et al., “Studies of Antimicrobial Activities of some 4-Thiazolidinone Fused Pyrimidines, [1,5]-Benzodiazepines and their Oxygen Substituted Hydroxylamine Derivatives”, Indian J. Pharm. Sci., 72:5 (2010), 607–612 | DOI
[12] Sharma P., Rane N., Gurram V. K., “Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents”, Bioorg. Med. Chem. Lett., 14:16 (2004), 4185–4190 | DOI
[13] H. W. Lee et al., “Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione”, Eur. J. Med. Chem., 40:9 (2005), 862–874 | DOI
[14] M.-Y. Jang et al., “Discovery of 7-N-piperazinylthiazolo[5,4-d]pyrimidine analogues as a novel class of immunosuppressive agents with in vivo biological activity”, J. Med. Chem., 54:2 (2011), 655–668 | DOI
[15] O. A. Fathalla et al., “Facile synthesis of fused pyrazolo[1,5-a]pyrimidinepyrazolo [1,5-a]triazines and N-sulphonamidopyrazoles as antiinflammatory”, Acta Pol. Pharm., 60:1 (2003), 51–60